Interventional cardiology in a whole new light

Open menu

News & Events

Opsens releases Q2 results

29 April 2014

Quebec City, Quebec, April 29, 2014 – Opsens Inc. (“Opsens” or” the Company”) (TSX-V: OPS) today released results for its second quarter ended February 28, 2014. SECOND QUARTER 2014 HIGHLIGHTS Opsens completes an $8.5 million equity financing; Opsens named to the 2014 TSX Venture top 50®; Opsens’ FFR products submitted for approval in Japan. RECENT…

Read more

Opsens grants Abiomed US$6M license

15 April 2014

Quebec City, Quebec, April 15, 2014 – Opsens Inc. (“Opsens” or “the Company”) (TSX-V: OPS) is pleased to announce it has entered into an Amended and Restated Co-Development Agreement (the “Agreement”) with Abiomed, Inc. (“Abiomed”) in connection with its miniature optical pressure sensor technology for applications in circulatory assist devices, such Agreement replacing the Co-Development…

Read more